Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

$5.7 million NIH grant supports research on why lean people develop insulin resistance

A Wayne State University research team was awarded a $5.7 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health focused on discovering the biological mechanisms that may help explain why some lean people develop insulin resistance while some people with obesity remain sensitive to insulin.

29 Sep 2026

C-Path awards $1.7 million to advance five drug development projects

Critical Path Institute (C-Path) today announced that its Translational Therapeutics Accelerator has awarded $1,699,500 through five Bridging Research and Innovation in Drug Development Grants (BRIDGe).

22 Sep 2026

New drug molecule reshapes protein to improve cancer target selectivity

A square peg doesn't fit a round hole. But what if the peg could change the shape of the hole?

16 Sep 2026

Zidesamtinib shows strong activity in TKI-naive ROS1-positive non-small cell lung cancer

New results from the global Phase I/II ARROS-1 trial showed clinically meaningful activity with zidesamtinib in patients with advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who had not previously received a tyrosine kinase inhibitor (TKI).

15 Sep 2026

Study links delayed Ewing sarcoma growth to reduced Trk and IGF1R pathway markers

A new research paper was published in Volume 17 of Oncotarget on August 7, 2026, titled "Delayed growth of SK-ES-1 Ewing sarcoma tumor xenografts is associated with reduced Trk and IGF1R pathway markers."

10 Aug 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026

Scientists uncover shared gene signatures that reveal how mammals age

Researchers mapped more than 11,000 transcriptomes across mice, rats, macaques, and humans, revealing conserved molecular signatures of aging and mortality across tissues, species, and cell types. The study developed interpretable transcriptomic clocks that track age, mortality-related molecular change, chronic disease signals and responses to lifespan-altering interventions.

29 May 2026

New therapies could help type 1 diabetes care move beyond insulin alone

Disease-modifying therapies for type 1 diabetes are beginning to move care beyond insulin replacement by targeting immune dysregulation, beta-cell stress, and preservation of endogenous beta-cell function. Teplizumab marks a major clinical milestone, but the review emphasizes that durable metabolic remission will likely require earlier screening, better patient selection, and sequential or combination therapies.

18 May 2026

Obesity may leave immune cells stuck in inflammatory mode after weight loss

A new EMBO Reports study suggests that obesity can leave a lasting epigenetic imprint on CD4 T cells, delaying the restoration of adaptive immune balance after weight loss. Using mouse models and human cohorts, researchers linked this immune “memory” to DNA methylation changes, saturated fatty acids, autophagy, and immune senescence.

28 Apr 2026

Combined CDK4/6 and EGFR inhibition improves pancreatic cancer therapy

Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare.

13 Mar 2026

Distinct gut toxicity patterns emerge with targeted cancer treatments

A new paper was published in Volume 13 of Oncoscience on February 6, 2026, titled "Gastrointestinal toxicity of targeted cancer therapies in the United States: Clinicopathologic patterns, FDA safety frameworks, and implications for national patient protection."

20 Feb 2026

Sino Biological's launch of SwiftFluo® TR-FRET Kits pioneers a new era in high- throughput kinase inhibitor screening

Sino Biological, Inc. is proud to announce the launch of its innovative SwiftFluo TR-FRET Kinase Assay Kits, a ready-to-use, high-performance solution designed to accelerate kinase activity detection and high-throughput kinase inhibitor screening.

From Sino Biological Inc. 21 Jan 2026

Accelerating kinase drug discovery with validated kinase activity assay kits

The development of new therapeutics targeting protein kinases is crucial in the fight against diseases like cancer.

From Eurofins Discovery 20 Jan 2026

Novel drug combination overcomes resistance in aggressive KRAS-mutated lung cancer

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and difficult-to-treat form of lung cancer.

13 Jan 2026

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Kinase inhibitors can accelerate the degradation of target proteins, study reveals

Protein kinases are the molecular switches of the cell. They control growth, division, communication, and survival by attaching phosphate groups to other proteins.

26 Nov 2025

Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC

The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Belzutifan demonstrates strong clinical activity in two rare neuroendocrine tumors

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated significant tumor shrinkage and disease control in patients with advanced pheochromocytoma and paraganglioma (PPGL), two rare and potentially life-threatening neuroendocrine tumors.

18 Oct 2025

Osimertinib plus chemotherapy improves survival in EGFR-mutated lung cancer

Treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.

17 Oct 2025

Blocking key protein restores healthy lung function and reduces fibrosis in mice

Pulmonary fibrosis is a deadly disease in which the lungs become thickened and scarred, gradually losing their ability to deliver oxygen to the body.

16 Oct 2025